Peter Attia· MD
that's the business end of the sars cov2 spike protein is that so-called receptor binding domain
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
that's the business end of the sars cov2 spike protein is that so-called receptor binding domain
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so when you make antibodies or those antibodies directed against the so-called part of the spike protein the receptor binding domain of the spike protein that is neutralizing the virus we want to neutralize the virus you don't want to just bind to the virus you want to neutralize it so it can't attach to cells